Update on the umbrella clinical trial of the PIONeeR project as of May 31, 2023
Enrollment in the biomarker study is now completed (see news from January 5, 2023) but remains open in the PIONeeR Project’s umbrella ...
Enrollment in the biomarker study is now completed (see news from January 5, 2023) but remains open in the PIONeeR Project’s umbrella ...
The RHU PIONeeR Project announces the completion of a major milestone with more than 450 patients enrolled in the biomarker part of the ...
The PIONeeR Project[1], a major international Hospital-University Research (RHU) project that addresses the critical challenge of resistance ...
One of the key steps in the PIOneeR protocol is biopsy processing by histopathology, which is performed at the pathology service led by Pr. ...
Following the third Scientific Advisory Board Meeting, which took place virtually on March 12th, 2021, and after seeing the project’s ...
A collection of brief summaries covering recent advances in immuno-oncology that we deem important from the perspective of The PIONeeR ...
The Pioneer Project is the first study to assess over 400 biomarkers for predictive value in advanced non-small cell lung cancers (NSCLC) ...
Levels of C5a circulating in COVID-19 patient plasma increase proportionally with the severity of the disease C5a and its receptor C5aR1, ...
Deciphering the response and resistance to immune-checkpoint inhibitors in lung cancer with artificial intelligence-based analysis: when ...
MI Day Lung Cancer - Meet our experts involved in the Pioneer Project
An original format of conference series: Time 1: world-class specialists and MI scientists discuss new research and innovation opportunities ...
This research study led to a better understanding of the immune mechanics at work in COVID-19 and provides insight into the cytokine storm ...
Led by Marseille Immunopole, the exploratory research project EXPLORE COVID-19 brings together the Marseille Public University Hospitals ...
Launched at the end of 2017, The Pioneer Project aims to understand and overcome resistance to anti-PD-1(L1) immunotherapies in patients ...
As of February 5, 2020, 11 partner centers are recruiting patients for the biomarker component of The Pioneer Project: Hôpital Nord/AP-HM, ...
An original format of conference series: Time 1: world-class specialists and MI scientists discuss new research and innovation opportunities ...
Pioneer Up #2: the latest news on immuno-oncology and lung cancer view from the Pioneer collective. Download here
As of December 23, 2019, The Pioneer Project RHU benefits from the commitment of 11 partner centers: Hôpital Nord/AP-HM, Hôpital Européen ...
This randomized clinical trial is one of the pillars of the multifaceted undertaking that is The Pioneer Project, a major international ...
As of November 7, 2019, The Pioneer Project RHU benefits from the commitment of 11 partner centers: Hôpital Nord/AP-HM, Hôpital Européen and ...
As of August 30, 2019, The Pioneer Project RHU benefits from the commitment of 11 partner centers: Hôpital Nord/AP-HM, Hôpital Européen and ...
Marseille, France, May 27, 2019 The Pioneer Project, a major international Hospital-University Research (RHU) project that aims to better ...
As of April 22, 2019, the Pioneer Project RHU benefits from the commitment of 11 partner centers: Hôpital Nord/AP-HM, Hôpital Européen and ...
Lung cancer screening, combinations around PD1(L1) immune checkpoint inhibitors, reclassification of solid tumors, prognostic and predictive ...
Within a newly formed ITN we are searching for 13 PhD students interested in anti-cancer responses of natural killer (NK) cells, the ...
“Inflammasomes in Health, Disease and Dysbiosis” Intervention of Richard Flavell, Yale University, New Haven, USA
“Antigen cross presentation and T cell activation by dendritic cells”, Intervention of Sebastian Amigorena, Institut Curie, Paris, FR
“What can we learn from the study of monogenic disorders of the immune system”, intervention of Alain Fischer, Institut Imagine, ...
Thursday 23 November 2017, 13:00 pm Boardroom of Aix-Marseille University Faculty of Medicine 27 Boulevard Jean Moulin, 13 385 Marseille ...
Fabrice Barlesi, MD, PhD, of Aix Marseille University and Assistance Publique Hôpitaux De Marseille, discusses in French phase III findings ...
“The HIV vaccine problem” intervention of Michel Nussenzweig, The Rockefeller University, New York, USA
Marc Daëron, Inserm, Paris, France
“Regulation and specificity of the mTOR signalling in immune cell growth and differentiation” intervention of Bing Su, Shanghai ...
“Cellular and molecular immunobiology - CIML” intervention of Pierre Glostein, CIML
“T cell recognition and tumor resistance in human cancer” intervention of Tom Schumacher, The Netherlands Cancer Institute, ...
“Principles of leukocytes navigation” intervention of Michael Sixt, Institute of Science and Technology Austria, Klosterneuburg, AU
“Microbiota-mediated defense against intestinal infection” intervention of Eric Pamer, Memorial Sloan Kettering Cancer Center, ...
“Evolution of lymphocyte-based immunity” Intervention of Max Cooper, Emory University, Atlanta, USA
“Innate immunity - CIML”, Intervention of Eric Vivier, CIML, Marseille, France
“Imaging Immunity: developing a spatiotemporal understanding of host defense”. Intervention of Ron Germain, NIH (National ...
“Genomics of tolerance” Intervention of Christophe Benoist, Harvard Medical School, Boston, USA
“Adaptive immunity - CIML” Intervention of Bernard Malissen,CIML
2016, the year of Immunology is also the 40th anniversary of CIML, a unique place for research and education in Immunology, at the ...
“CIML and Serendipity”, intervention of Michel Fougereau, CIML, Marseille, France
Identifying novel T cell checkpoints via quantitative proteomic of signalosomes in primary T cells T cells probe the surface of dendritic ...
Conférence d’introduction par Bruce BEUTLER, Professeur Régent et directeur du Center for the Genetics of host defense à l’Université ...
Introduction par le Pr Eric VIVIER, Directeur du CIML, Coordinateur de MI-mAbs, Professeur d’Immunologie à la Fa- culté de Médecine de ...